The combination of radiotherapy and chemotherapy has significantly improved survival rates for patients with nasopharyngeal carcinoma (NPC). Nonetheless, some patients still experience poor outcomes, potentially due to resistance to cisplatin, a widely used chemotherapeutic agent. Scutellarein, a compound extracted from